Melvin Lafeber

Melvin Lafeber is a researcher in the Department of Internal Medicine at Erasmus MC, actively contributing to clinical and pharmacological research with a focus on cardiovascular disease, hypertension, and COVID-19 outcomes. His work emphasizes combination therapies, polypill strategies, and risk assessment in diverse patient populations.

Research Interests: His primary research areas include cardiovascular risk, lipid metabolism, polypill-based prevention, renal denervation for resistant hypertension, and the long-term impact of frailty and triage decisions in hospitalized patients with infectious diseases. He investigates both pharmacological interventions and clinical decision-making processes.

Publication Trends: His recent publications, spanning from 2020 to 2025, reflect a strong focus on clinical trials, cohort studies, and meta-analyses in cardiovascular and infectious disease medicine. Key themes include the durability of interventional therapies, immunogenicity of vaccines, and the impact of multidrug regimens on patient outcomes.

Scientific Collaborations: Dr. Lafeber is a key contributor to several major research consortia, including the COMET Research Team, COOP-research group, RADIANCE-HTN Investigators, and SWITCH ON Research Group, indicating extensive national and international collaboration.

Advising and Grants: While no direct information on students or grants is available in the provided text, his involvement in large-scale, multi-center studies suggests participation in significant grant-funded research projects and potential mentorship within collaborative teams.

Laboratories and Research Teams: He is embedded within collaborative networks such as the COMET and SWITCH ON research groups, which likely operate within structured research units at Erasmus MC focused on infectious diseases and cardiovascular pharmacology.